C4 Therapeutics, Roche Ink USD 1 Billion Cancer Drug Deal for Novel DAC Therapies
Written By : sheeba farhat
Published On 2026-04-12 05:00 GMT | Update On 2026-04-12 18:50 GMT
New Delhi: C4 Therapeutics, opens new tab said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche, opens new tab that could be worth more than USD 1 billion.
- The companies will collaborate on two programs to develop degrader-antibody conjugates against undisclosed oncology targets exclusive to the agreement.
- Degrader-antibody conjugates (DAC) are an emerging class of cancer therapies that combine antibody-drug conjugation with targeted protein degradation technology.
- Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.
- C4T will receive a $20 million upfront payment for the two programs. If Roche exercises its option for a third target, C4T will receive an additional payment.
- C4T is also eligible to receive over $1 billion in discovery, regulatory and commercial milestone payments, and entitled to tiered royalties on future sales.
- The agreement marks the third collaboration between the two companies and extends a relationship that began in 2016.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.